Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary FibrosisBusiness Wire • 05/22/23
Bristol-Myers Squibb Company (BMY) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)Seeking Alpha • 05/13/23
Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023Business Wire • 05/11/23
Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?The Motley Fool • 05/05/23
Want Passive Income at a Fair Price? Consider Buying This Dividend Growth StockThe Motley Fool • 05/03/23
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior TherapyBusiness Wire • 05/03/23
Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare ConferenceBusiness Wire • 05/02/23
U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)Business Wire • 05/01/23
Bristol Myers Squibb's TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response RateBusiness Wire • 05/01/23
Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt SalesZacks Investment Research • 04/27/23
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)Business Wire • 04/26/23